Unveiling Circulating Targets in Pancreatic Cancer: Insights from Proteogenomic Evidence and Clinical Cohorts

Haokang Feng,Zhixue Chen,Jianang Li,Jiale Feng,Fei Yang,Fansheng Meng,Hanlin Yin,Yuquan Guo,Huaxiang Xu,Yuxin Liu,Runjie Liu,Wenhui Lou,Liang Liu,Xu Han,Hua Su,Lei Zhang
DOI: https://doi.org/10.1101/2024.02.08.24302497
2024-02-11
Abstract:Pancreatic cancer (PC), lacking biomarkers and effective therapeutics, remains highly lethal. Data regarding the correlations of PC risk and the individual plasma proteome known for minimally cancer biomarkers, are scarce. Here, we measure 1,345 human plasma proteins via Proteome-Wide Association Studies, presenting 78 proteins are prominently related to PC risk, including 4 proteins (ROR1, FN1, APOA5, ABO) exhibit the strongest causal association identified via Mendelian Randomization and Colocalization. Our two independent cohorts further demonstrate FN1 and ABO are highly expressed in blood or tumors from patients with PC compared to specimens from healthy individuals or para-tumors. Moreover, patients with higher levels of FN1 and ABO in their blood or tumors have worse median survival than those with lower levels. Multiple drugs targeting FN1 are currently available or undergoing clinical testing, making FN1 a promisingly repurposed therapeutic target in addition to severing as a circulating prognostic indicator for PC.
Oncology
What problem does this paper attempt to address?